Drug interactions
Infigratinib + Netupitant-palonosetron
Severity: Moderate
Infigratinib and Netupitant-palonosetron: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Netupitant, a moderate CYP3A4 inhibitor, can increase infigratinib exposure. This may increase toxicities such as hyperphosphatemia, ocular effects and fatigue.
What this interaction means in plain words
Infigratinib and Netupitant-palonosetron can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
CYP3A4 inhibition by netupitant reduces infigratinib metabolism.
What to do
Prefer an antiemetic without CYP3A4 inhibition. If used together, monitor for infigratinib toxicity, including phosphate and eye symptoms.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Infigratinib and Netupitant-palonosetron, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Netupitant-palonosetron
- Apomorphine + Netupitant-palonosetron Contraindicated
- Flibanserin + Netupitant-palonosetron Contraindicated
- Apalutamide + Netupitant-palonosetron Major
- Avapritinib + Netupitant-palonosetron Major
- Carbamazepine + Netupitant-palonosetron Major
- Cobimetinib + Netupitant-palonosetron Major
Frequently asked questions
Can I take Infigratinib with Netupitant-palonosetron?
MediHelp rates the interaction as moderate. Infigratinib and Netupitant-palonosetron can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Netupitant, a moderate CYP3A4 inhibitor, can increase infigratinib exposure. This may increase toxicities such as hyperphosphatemia, ocular effects and fatigue.
How serious is the interaction between Infigratinib and Netupitant-palonosetron?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer an antiemetic without CYP3A4 inhibition. If used together, monitor for infigratinib toxicity, including phosphate and eye symptoms.
What other medicines interact with Netupitant-palonosetron?
MediHelp also lists interactions of Netupitant-palonosetron with, for example, Apomorphine, Flibanserin, Apalutamide. The full list is on the Netupitant-palonosetron page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
